Breast
Trial Name: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Trial Number: A011401
Trial Name: A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast cancer: The ABC Trial
Trial Number: A011502
Trial Name: Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
Trial Number: SWOG S1207
Trial Name: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Trial Number: NRG BR003
Trial Name: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Trial Number: NSABP B-55/BIG 6-13
Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
Trial Name: A Prospective, Multicenter, Observational Study, Examining the Clinical Utility of CANscript in Routine Clinical Practice
Trial Number: ANCERs
Lung
Trial Name: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Trial Number: ALCHEMIST (A081105)
Trial Name: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Trial Number: ALCHEMIST (E4512)
Trial Name: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Trial Number: ALCHEMIST (A151216)
Trial Name: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)
Trial Number: ALCHEMIST (EA5142)
Trial Name: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Trial Number: S1400
Trial Name: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)
Trial Number: S1400I
Trial Name: A Phase II Study of MEDI14736 (DURVALUMAB) plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD1/Anti-PDL-1 Resistant Stage IV Squamous Cell Lung Cancer (LUNG-MAP NON-MATCH SUB-STUDY)
Trial Number: S1400F
Trial Name: A Phase II Study of Talazoparab (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map NON-Sub-Study)
Trial Number: S1400G
Trial Name: A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
Trial Number: S1400K
Trial Name: Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab
Trial Number: HCRN 15-233
Multiple Myeloma
Trial Name: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Trial Number: ECOG E1A11
Pancreas
Trial Name: Phase II Randomized, Double-Blind Stufy of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients
Trial Number: HCRN GI14-198
Urothelial (Bladder, Urethra, Ureter)
Trial Name: A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Trial Number: GU14-182
NOTE: Trials open and close regularly at different times. To make sure a trial is still open, call 219-836-6875.
It takes 14 years for an experimental drug to travel from the laboratory to U.S. consumers. The longest part of that process is finding people to participate in each phase of clinical trials. The more people who take part, the faster we will find better ways to treat and prevent cancer.
The purpose of the cancer research clinical trials offered at our local hospitals is to gather and evaluate information about new medications that are not yet approved by the FDA. Sometimes, a clinical trial will involve a drug already approved by the FDA for one purpose, but that is being evaluated for another use.
It is important to note that every person participating in a cancer clinical trial receives treatment. While the word placebo may be included in the trial description, patients receive, at minimum, the best standard treatment in conjunction with the study medications. Placebo in these cases does NOT mean the patient is not receiving any treatment.
People choose to participate in clinical trials for many reasons. Some have exhausted all other therapy options and wish to try experimental treatment to help prolong or improve quality of life. Others wish to have access to new therapies that may benefit them, with faster healing or less side effects. Still others feel a strong sense of commitment to helping advance cancer research and help identify new therapies for those diagnosed in the future.
The Community Cancer Foundation sponsors research trials at the three hospitals of the Community Healthcare System: Community Hospital in Munster; St. Catherine Hospital in East Chicago; and St. Mary Medical Center in Hobart. The Foundation provides area residents with access to...
- Phase II clinical trials sponsored by the Hoosier Oncology Group (HOG) for a variety of metastatic cancers.
- Phase III clinical trials sponsored by the Cancer Trials Support Unit (CTSU) supported by the National Cancer Institute for most cancer sites.
- Other clinical trials sponsored by pharmaceutical companies.